HMB Dosage: 3g/Day Split Three Ways; Timing Matters More for HMB-FA

By Erin Rose · Updated July 19, 2026 · Methodology

Educational summary — not medical advice. HMB is not an approved treatment for any condition; dosing decisions for older adults or clinical muscle-wasting risk should involve a clinician. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why 3g/day, and why timing is historical convention, not proven precision

Every human HMB trial in this cluster's evidence base — from the field's founding paper, Nissen et al. 1996 (which also tested 1.5g/day in one arm), through the independent Rowlands 2009 and Sanchez-Martinez 2018 meta-analyses, to the industry-funded Wilson 2014 and Lowery 2016 trained-athlete trials — converges on 3g/day as the studied dose. There is no meaningfully different higher-dose protocol tested in humans: 3g/day is both the floor and the ceiling of what's been studied. The Wilson 2014/Lowery 2016 protocol split this into 1g pre-exercise (about 30 minutes before training) and 1g with each of the two main meals, with three meal-timed 1g doses on non-training days — a convention that mirrors the original Nissen 1996 design. No trial in this pack isolates timing as an independent variable, so treat split dosing as historical practice worth following for consistency, not as precision-timed evidence.

Ca-HMB vs. HMB-FA: a real kinetic difference, an unproven outcome difference

Fuller et al. 2011, a randomized crossover pharmacokinetics study (all 5 authors employed by Metabolic Technologies, Inc.), found HMB-FA reaches peak plasma HMB in about 38 minutes vs. 128 minutes for Ca-HMB (p<0.0001), at a peak concentration of roughly 249 µmol/L vs. 131 µmol/L for Ca-HMB (p<0.0001) — nearly double, with AUC almost doubled for the free-acid form too. That kinetic data is not disputed elsewhere in the literature. But two mechanistic tracer studies suggest the practical gap may matter less than the numbers imply: Wilkinson et al. 2013 found HMB-FA increased acute muscle protein synthesis (MPS) by 70% and reduced muscle protein breakdown (MPB) by 57%, while Wilkinson et al. 2018 (an MTI-funded academic study) found Ca-HMB produced a "comparable stimulation to MPS and suppression of MPB, to FA-HMB" in its own tracer study — despite the slower, lower plasma peak. The honest framing: HMB-FA gets into the blood faster and higher, but nothing in this evidence base shows that difference changes real-world strength or muscle-mass outcomes independently of the small, industry-funded trial lineage that used it. Ca-HMB is the cheaper, equally mechanistically-supported default; HMB-FA is a "kinetics matter to you and price doesn't" upgrade, not a proven-superior one. See best HMB for cost comparison.

No established Upper Limit — treat 3g/day as the ceiling, not a floor to build on

There is no established Tolerable Upper Intake Level for HMB. 3g/day is well-tolerated across every trial reviewed in this evidence base, with no significant adverse-event signal reported. But that reflects the dose every trial actually tested — not a demonstrated safety ceiling at higher amounts, since doses above 3g/day simply aren't meaningfully studied in humans here. Treat 3g/day as the well-studied amount, not a starting point to scale up from.

Population-specific note: no separate clinical dose

Unlike some clusters where a clinical population uses a distinct, higher protocol, HMB does not: Deutz et al. 2013's older-adult bed-rest trial used the identical 3g/day (1.5g twice daily) protocol as the trained-athlete trials. There is no separate "clinical dose" distinct from the standard consumer 3g/day in this evidence base.

Frequently asked questions

Related

• HMB: what it actually does, honestly explained
• Best HMB — ranked by cost per 3g dose
• HMB for muscle loss
• Does HMB actually work?
• Protein — whole dietary protein already supplies the leucine HMB is derived from

Sources